ErbB公司
曲妥珠单抗
单克隆抗体
细胞生物学
表皮生长因子受体
受体
信任
信号
生物
癌症研究
乳腺癌
抗体
癌症
信号转导
免疫学
生物化学
遗传学
计算机科学
机器学习
作者
Yosef Yarden,Mark X. Sliwkowski
摘要
When epidermal growth factor and its relatives bind the ErbB family of receptors, they trigger a rich network of signalling pathways, culminating in responses ranging from cell division to death, motility to adhesion. The network is often dysregulated in cancer and lends credence to the mantra that molecular understanding yields clinical benefit: over 25,000 women with breast cancer have now been treated with trastuzumab (Herceptin), a recombinant antibody designed to block the receptor ErbB2. Likewise, small-molecule enzyme inhibitors and monoclonal antibodies to ErbB1 are in advanced phases of clinical testing. What can this pathway teach us about translating basic science into clinical use?
科研通智能强力驱动
Strongly Powered by AbleSci AI